Peakdale Molecular Reports Significant Growth in Demand for its Medicinal Chemistry Services

25 Jun 2014
Kerry Parker
CEO

Peakdale Molecular, a leading UK provider of medicinal chemistry and chemistry services, is celebrating its most successful year ever for revenues and earnings since the company’s inception in 1992. Offering specialised chemistry services for early phase drug and diagnostics discovery, Peakdale has experienced a significant increase in demand from pharma R&D operations in particular. Following long-term investment in facilities and expertise, together with a strategic evolution of its offering, the company has been awarded multiple contracts over the past 12 months, from new and returning customers.

As R&D cost pressures increase, many pharma companies are restructuring their R&D operations to accommodate a greater emphasis on outsourcing, notably in the specialised chemistry space. Having built up a highly qualified team of over 100 organic chemists across two major facilities, Peakdale has been well placed to respond to this demand, providing a range of drug discovery services with a focus on delivering skilled, innovative solutions. The company has expanded in both research chemistry services, in which Peakdale provides chemists and facilities on a Full-Time Equivalent basis, and increasingly in custom synthesis work on a Fee-for-Service basis. In particular, the ongoing development of Peakdale’s service offering for biological sciences, such as ADME Tox services, has seen increasing traction and has successfully enabled Peakdale to support a wider group of both pharma and biotech clients.

Dr Ray Fisher, CEO at Peakdale Molecular, commented: “Peakdale’s extensive industry knowledge and strong commitment to providing high quality, flexible and customer-orientated services, ensures we can provide true problem-solving capabilities for the challenges encountered in R&D. So when our customers outsource their R&D chemistry to us, they know that we won’t just do the work, we’ll add significant value to their drug discovery process. Over the last year this has been borne out by a pick-up in business from both new and returning customers.”

Together with significant growth in its traditional market in the UK and mainland Europe, Peakdale has seen made good progress in the US which the company anticipates will be a source of major growth for the company in the present fiscal year.


In Vitro ADMET Services

Peakdale Molecular

At Peakdale we offer a range of in vitro ADMET predictive models, delivering accurate and reproducible data, maintaining a focus on efficient turnaround times to facilitate our customers' drug discovery programs. In addition to our core assays, we also offer our clients the flexibility of bespoke assay design. The majority of our assays utilise sensitive "state of the art" triple quad LC-MS/MS ESI detection. Complementing our laboratory facilities, we have an in silico capability dedicated to virtual high throughput screening, optimising ADMET properties to aid rational compound selection for in vitro experiments. We support our clients with results interpretation and direct communication with our assay experts. Features: Solubility Lipophilicity Permeability Plasma protein binding Metabolic stability CYP450 metabolic inhibition CYP induction Cytotoxicity In silico modelling Customer specific assays

(0)

Medicinal Chemistry Services

Peakdale Molecular

Peakdale has built up medicinal chemistry and computational chemistry expertise across therapeutic areas and spanning the drug discovery process from hit generation to Phase I clinical studies. Peakdale has a proven track record of success in producing robust candidates suitable for Proof-of-concept testing in vivo. To achieve this, the company utilises its highly experienced and committed teams to deliver on project goals and ensure complete client confidentiality and protection of Intellectual Property (IP). Services include: Hit Generation Hit-to-lead Lead optimisation Scale-up Scaffold-hopping

(0)

Links

Tags